JP7677976B2 - Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 - Google Patents
Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 Download PDFInfo
- Publication number
- JP7677976B2 JP7677976B2 JP2022538813A JP2022538813A JP7677976B2 JP 7677976 B2 JP7677976 B2 JP 7677976B2 JP 2022538813 A JP2022538813 A JP 2022538813A JP 2022538813 A JP2022538813 A JP 2022538813A JP 7677976 B2 JP7677976 B2 JP 7677976B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- carbonitrile
- naphthyridine
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911053558 | 2019-12-23 | ||
| IN201911053558 | 2019-12-23 | ||
| PCT/US2020/066510 WO2021133752A1 (en) | 2019-12-23 | 2020-12-22 | Substituted heteroaryl compounds useful as t cell activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508054A JP2023508054A (ja) | 2023-02-28 |
| JP2023508054A5 JP2023508054A5 (https=) | 2024-01-04 |
| JP7677976B2 true JP7677976B2 (ja) | 2025-05-15 |
Family
ID=74195155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538813A Active JP7677976B2 (ja) | 2019-12-23 | 2020-12-22 | Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230086933A1 (https=) |
| EP (1) | EP4081524B1 (https=) |
| JP (1) | JP7677976B2 (https=) |
| KR (1) | KR20220119458A (https=) |
| CN (1) | CN114846015B (https=) |
| AU (1) | AU2020412472A1 (https=) |
| BR (1) | BR112022012204A2 (https=) |
| CA (1) | CA3163003A1 (https=) |
| ES (1) | ES3013568T3 (https=) |
| IL (1) | IL294273A (https=) |
| MX (1) | MX2022007372A (https=) |
| WO (1) | WO2021133752A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294085A (en) * | 2019-12-19 | 2022-08-01 | Bristol Myers Squibb Co | Combinations of dgk inhibitors and checkpoint antagonists |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023011456A1 (en) * | 2021-08-03 | 2023-02-09 | Beigene, Ltd. | Pyrazolopyridinone compounds |
| WO2023122772A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| CN118451073A (zh) * | 2021-12-29 | 2024-08-06 | 百济神州有限公司 | 杂环化合物 |
| WO2023150186A1 (en) * | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| EP4486741A4 (en) * | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| CN118974049A (zh) * | 2022-03-31 | 2024-11-15 | 益方生物科技(上海)股份有限公司 | 激酶抑制剂，其制备方法和用途 |
| US20250215014A1 (en) * | 2022-03-31 | 2025-07-03 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| CN119677740A (zh) * | 2022-08-09 | 2025-03-21 | 百时美施贵宝公司 | 用作t细胞活化剂的叔胺取代的双环化合物 |
| EP4658650A1 (en) * | 2023-02-02 | 2025-12-10 | Beone Medicines I GmbH | Heterocyclic compounds |
| EP4658655A1 (en) * | 2023-02-02 | 2025-12-10 | Beone Medicines I GmbH | Condensed heterocyclic compounds as inhibitor of diacylglycerol kinases |
| JP2026505790A (ja) * | 2023-02-02 | 2026-02-18 | ビーワン メディシンズ ワン ゲーエムベーハー | ジアシルグリセロールキナーゼの阻害剤としての縮合ヘテロ環式化合物 |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2025030002A2 (en) * | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025051110A1 (en) * | 2023-09-04 | 2025-03-13 | Insilico Medicine Ip Limited | Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020071550A1 (ja) | 2018-10-04 | 2020-04-09 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2544939B2 (ja) * | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | ベンゾヘテロ環誘導体 |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EA201591746A1 (ru) * | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| KR102767739B1 (ko) * | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| CN112585139B (zh) * | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
-
2020
- 2020-12-22 BR BR112022012204A patent/BR112022012204A2/pt not_active IP Right Cessation
- 2020-12-22 IL IL294273A patent/IL294273A/en unknown
- 2020-12-22 EP EP20845305.0A patent/EP4081524B1/en active Active
- 2020-12-22 KR KR1020227025312A patent/KR20220119458A/ko active Pending
- 2020-12-22 MX MX2022007372A patent/MX2022007372A/es unknown
- 2020-12-22 AU AU2020412472A patent/AU2020412472A1/en not_active Abandoned
- 2020-12-22 JP JP2022538813A patent/JP7677976B2/ja active Active
- 2020-12-22 CN CN202080089546.2A patent/CN114846015B/zh active Active
- 2020-12-22 US US17/785,585 patent/US20230086933A1/en active Pending
- 2020-12-22 WO PCT/US2020/066510 patent/WO2021133752A1/en not_active Ceased
- 2020-12-22 ES ES20845305T patent/ES3013568T3/es active Active
- 2020-12-22 CA CA3163003A patent/CA3163003A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020071550A1 (ja) | 2018-10-04 | 2020-04-09 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
Non-Patent Citations (2)
| Title |
|---|
| Biochemical Pharmacology，2000年，Vol. 59，No. 7，pp. 763-772 |
| DATABASE STN REGISTRY file，[online], RN 2324027-31-6, Entered STN: 04 Jun 2019, RN 2324040-93-7, Entered STN: 04 Jun 2019, RN 896634-20-1, Entered STN: 28 Jul 2006, RN 877808-10-1, Entered STN: 23 Mar 2006, RN 877647-18-2, Entered STN: 22 Mar 2006, RN 874463-49-7, Entered STN: 17 Feb 2006, RN 874463-50-0, Entered STN: 17 Feb 2006, RN 862486-67-7, Entered STN: 06 Sep 2005, RN 862487-66-9, Entered STN: 06 Sep 2005, RN 849918-13-4, Entered STN: 06 May 2005 等、 [retrieved on 31 Oct. 2024] |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114846015A (zh) | 2022-08-02 |
| IL294273A (en) | 2022-08-01 |
| JP2023508054A (ja) | 2023-02-28 |
| US20230086933A1 (en) | 2023-03-23 |
| EP4081524B1 (en) | 2025-01-29 |
| MX2022007372A (es) | 2022-07-12 |
| CA3163003A1 (en) | 2021-07-01 |
| CN114846015B (zh) | 2024-07-30 |
| KR20220119458A (ko) | 2022-08-29 |
| BR112022012204A2 (pt) | 2022-09-13 |
| AU2020412472A1 (en) | 2022-08-18 |
| WO2021133752A1 (en) | 2021-07-01 |
| ES3013568T3 (en) | 2025-04-14 |
| EP4081524A1 (en) | 2022-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7677976B2 (ja) | Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 | |
| JP7653441B2 (ja) | Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物 | |
| CN114846007B (zh) | 可用作t细胞激活剂的经取代的喹唑啉基化合物 | |
| TWI836159B (zh) | 可作為helios蛋白質抑制劑之化合物 | |
| TWI843922B (zh) | 可作為t細胞活化劑之經取代雙環化合物 | |
| JP7712274B2 (ja) | Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体 | |
| RS64285B1 (sr) | Jedinjenja naftiridinona korisna kao aktivatori t ćelija | |
| JP2025528134A (ja) | Ｔ細胞活性化剤として有用な置換テトラゾリル化合物 | |
| JP2025528157A (ja) | Ｔ細胞活性化剤として有用な第三アミン置換二環式化合物 | |
| EA047609B1 (ru) | Замещенные гетероарильные соединения, полезные в качестве активаторов т-клеток | |
| EA048870B1 (ru) | Замещенные оксоизоиндолины | |
| EA048427B1 (ru) | Замещенные бициклические соединения, применимые в качестве активаторов т-клеток |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231221 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250430 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250501 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7677976 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |